On August 20, 2007 at 3:30 pm E.D.T. Geert Kersten, Chief ExecutiveOfficer, will give a 25-minute presentation regarding CEL-SCI's late stagecancer drug Multikine(R). Mr. Kersten will also participate in a question andanswer session following the presentation and one-on-one meetings throughoutthe day.
Advertisement
The presentation with streaming video and PowerPoint presentation will bewebcast live and archived on the websites of CEL-SCI at www.cel-sci.com, andNoble Financial's conference website at www.two-007.net. It is recommendedthat interested parties register at least 15 minutes prior to the start of thepresentation to ensure timely access.
Advertisement
About CEL-SCI's Phase III Cancer Drug Multikine:
In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median ofthree and a half years following surgery. The U.S. Food and DrugAdministration (FDA) gave the go-ahead for a Phase III clinical trial withMultikine in January 2007 and granted orphan drug status to Multikine in theneoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neckin May 2007.
Multikine, a patented defined mixture of naturally derived cytokines, isthe first immunotherapeutic agent in a new class of drugs called "ImmuneSIMULATORS". Immune SIMULATORS simulate the way our natural immune systemacts in defending us against cancer. As opposed to other immunotherapies whichare designed to target a single or limited number of specific antigens ormolecules, Immune SIMULATORS are multi-targeted; they simultaneously cause adirect and targeted killing of the specific tumor cells and they activate theimmune system to produce a stronger anti-tumor attack on multiple fronts.
Multikine is also the first immunotherapeutic agent being developed as afirst-line standard of care treatment for cancer. It is administered prior toany other cancer therapy because that is the period when the anti-tumor immuneresponse can still be fully activated. Once the patient has advanced disease,or had surgery or has received radiation and/or chemotherapy, the immunesystem is severely weakened and is less able to mount an effective anti-tumorimmune response. Other immunotherapies are administered after the patient hasreceived chemotherapy and/or radiation therapy, which can limit theireffectiveness.
The Company has operations in Vienna, Virginia and Baltimore, Maryland.CEL-SCI's other products, which are currently in pre-clinical stage, haveshown protection against a number of diseases in animal tests and are beingtested against diseases associated with bio-defense and avian flu.
SOURCE CEL-SCI Corporation
